WHO suggests usage of dexamethasone steroid for critical Covid-19 cases

The preliminary trial was conducted over random 2,100 hospitalised Covid-19 patients, and about 4,300 hospitalized Covid-19 patients who were randomized to receive the usual standard of care

The World Health Organisation (WHO) on Sunday (local time) emphasised on a rapid increase in production of dexamethasone, a cheap steroid which after clinical trials has shown life-saving potential for critically ill Covid-19 patients.

According to researchers from Oxford University, a low-dose regimen of dexamethasone, which is typically used to treat certain forms of arthritis, severe allergies, asthma, and certain types of cancer, for 10 days was found to reduce the risk of death by a third among hospitalized patients requiring ventilation in the trial.

The preliminary trial was conducted over random 2,100 hospitalised Covid-19 patients, and about 4,300 hospitalized Covid-19 patients